$166.13
1.47[0.89%]
Last update: 1:57PM Get Real Time Here
Latest News for AbbVie Stock (NYSE:ABBV)
AbbVie Stock (NYSE: ABBV)
Categories: All
Thursday, April 18, 2024
- Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease StudyVandana Singh - 1 day ago
- AbbVie Announces Phase 3 SELECT-GCA Study Of Upadacitinib Results In Patients With Giant Cell Arteritis; In Combination With A 26-week Steroid Taper Regimen Achieved Its Primary Endpoint Of Sustained Remission; Key Secondary Endpoints Were Also MetBenzinga Newsdesk - 1 day ago
Wednesday, April 17, 2024
Tuesday, April 16, 2024
- Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst UpgradesVandana Singh - 2 days ago
- FDA Says Counterfeit Version Of Botox Found In Multiple States; Alerting Health Care Professionals & Consumers That Unsafe Counterfeit Versions Of Botox Found In Multiple States & Administered To Consumers; Currently, There Is No Indication That The Reported Events Were Linked To Abbvie's FDA-Approved Botox; Aware Of Adverse Events, Including Hospitalizations, Linked To Counterfeit BotoxBenzinga Newsdesk - 3 days ago
Monday, April 15, 2024
Friday, April 12, 2024
- What's Going On AbbVie Stock On Friday?Vandana Singh - 6 days ago
- Smart Money Is Betting Big In ABBV OptionsBenzinga Insights - Apr 12, 2024, 10:04AM
- AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA) for Preventive Treatment of MigraineBenzinga Newsdesk - Apr 12, 2024, 7:31AM
Wednesday, April 10, 2024
Friday, April 05, 2024
Thursday, April 04, 2024
Wednesday, April 03, 2024
- AbbVie Says Q1 2024 Adj Diluted Earnings Per Share Guidance Range, Including Impact Of Q1 2024 Acquired IPR&D And Milestones Expense, Is $2.18-$2.22; Reported GAAP Earnings For Q1 Of 2024 Are Expected To Include Acquired IPR&D And Milestones Expense Of $164M On A Pre-tax BasisBenzinga Newsdesk - Apr 3, 2024, 4:27PM
- AbbVie Inc Says Adjusted Non-GAAP Earnings For Q1 Of 2024 Are Expected To Include Acquired IPR&D And Milestones Expense Of $164M On A Pre-Tax Basis; 2024 Adj Diluted EPS Guidance Range, Including Impact Of First Quarter 2024 Acquired IPR&D And Milestones Expense, Is $10.97-$11.17.Benzinga Newsdesk - Apr 3, 2024, 4:26PM
- 10 Health Care Stocks Whale Activity In Today's SessionBenzinga Insights - Apr 3, 2024, 1:35PM
- FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The LandscapeVandana Singh - Apr 3, 2024, 10:02AM
Thursday, March 28, 2024
Wednesday, March 27, 2024
Tuesday, March 26, 2024
Monday, March 25, 2024
- Nasdaq Turns Higher; Akanda Shares PlungeAvi Kapoor - Mar 25, 2024, 3:00PM
- Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day SessionAvi Kapoor - Mar 25, 2024, 2:44PM
- Crude Oil Moves Higher; US New Home Sales Fall In FebruaryAvi Kapoor - Mar 25, 2024, 11:54AM
- Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday?Vandana Singh - Mar 25, 2024, 11:27AM
- US Stocks Down; Chicago Fed National Activity Index Rises In FebruaryAvi Kapoor - Mar 25, 2024, 9:42AM
- AbbVie To Acquire Landos Biopharma At A Price Of $20.42 Per Share In Cash Upon Closing, Or ~$137.5MBenzinga Newsdesk - Mar 25, 2024, 8:32AM
Friday, March 22, 2024
- The Latest Analyst Ratings For AbbVieBenzinga Insights - Mar 22, 2024, 3:01PM
- FDA Approves Mirvetuximab Soravtansine-Gynx For FRA Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal CancerBenzinga Newsdesk - Mar 22, 2024, 2:30PM
- Guggenheim Maintains Buy on AbbVie, Raises Price Target to $190Benzinga Newsdesk - Mar 22, 2024, 2:02PM
Thursday, March 21, 2024
Tuesday, March 19, 2024
Monday, March 18, 2024
Thursday, March 14, 2024
Monday, March 11, 2024
Friday, March 08, 2024
Wednesday, March 06, 2024
Tuesday, March 05, 2024
- JUVÉDERM VOLUMA XC For Temple Hollows Receives U.S. FDA ApprovalBenzinga Newsdesk - Mar 5, 2024, 8:18AM
- Dragonfly Therapeutics Received A Milestone Payment Following Dosing Of The First Patient In A Clinical Trial Conducted By AbbVie To Evaluate Abbv-303, A Solid Tumor Targeting TriNKETBenzinga Newsdesk - Mar 5, 2024, 7:17AM
Friday, March 01, 2024
Wednesday, February 28, 2024
Monday, February 26, 2024
Thursday, February 22, 2024
- Cosette Pharmaceuticals Announces The Approval And Launch Of First Generic Version Of RECTIV Ointment, 0.4%, With 180 Days Competitive Generic Therapy Exclusivity; RECTIV Is Registered Trademark Of AbbVieBenzinga Newsdesk - Feb 22, 2024, 8:53AM
- AbbVie Collaborates With Tentarix To Develop Conditionally-Active, Multi-Specific Biologics For Oncology And ImmunologyBenzinga Newsdesk - Feb 22, 2024, 8:06AM